Chengdu Kanghua Biological Products' financials remain strong despite stock price drop. High ROE, impressive net income growth, and a high profit retention rate suggest effective management and strategic reinvestment.

Chengdu Kanghua Biological Products' low P/E ratio is due to poor earnings and low growth expectations. Investors doubt the company's earnings potential, which is reflected in the low P/E ratio. The share price is unlikely to rise significantly soon.

Chengdu Kanghua Biological's low P/E ratio, poor earnings and projected growth below market average may impact future share price. A significant rise in share price is unlikely in the near future.